about us

“The greatest need we have today in the human cancer problem, except for a universal cure, is a method for detecting cancer before there are any clinical signs or symptoms.”

Sidney Farber, M.D.
Father of modern chemotherapy
November 1962

Our logo reflects our bold ambition to fundamentally change cancer care, for everyone.

pioneering the
detection of early
cancer

Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. Incubated within Flagship Pioneering for three years before launching in 2021, Harbinger combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test.

A harbinger is a “forerunner, that which precedes and gives notice of the coming of another.” We not only are working to identify the harbinger – the biological programs present in the earliest forms of cancer – but seek to be the harbinger, to be the forerunner which will usher in the future of healthcare.

At Harbinger, we intend to lead in shaping this future – creating a proactive paradigm so that people can live cancer-free for longer, adding years to life and life to years. We envision a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies.

Our answer to the problem of late cancer detection and unacceptable patient prognoses starts with our proprietary solutions for the future of cancer pre-emption. Beginning with blood-based tests, we will enable cancer detection before it is visible. By identifying biological programs rooted in cancer’s origins, we can enable identification of early stage and pre-disease. Through this new pathway for cancer diagnosis and early therapeutic interventions, Harbinger Health has the potential to fundamentally change cancer care, for everyone.

our leadership team

Stephen Hahn, M.D.

Chief Executive Officer

Dymeka Harrison

Chief Commercial Officer

Vince Lozada

Chief Financial Officer

May Orfali, M.D., M.B.A.

Chief Medical Officer

Gisela Paulsen

Chief Operating Officer

Tony Shuber

Chief Innovation Officer

Keiran Chacko, Ph.D.

Head of Data Science and Strategy

Leila Gjika

SVP, Head of Human Resources

Eric Haltom

SVP Clinical Operations

Feras Hantash, M,S., Ph.D.

SVP, CLIA Lab Director

David Lambe

SVP, Portfolio Strategy and Operations

our scientific co-founders

Prof. Alexander Meissner, Ph.D.

Scientific Advisory Board & Co-Founder

Prof. Franziska Michor, Ph.D.

Scientific Advisory Board & Co-Founder

Prof. Zachary Smith, Ph.D.

Scientific Advisory Board & Co-Founder

our board of directors

Doug Cole, M.D.

Co-Founder & Managing Partner, Flagship Pioneering

Lord Ara Darzi, M.D.

Chairman, Pre-emptive Medicine & Health Security, Flagship Pioneering

Margo Georgiadis

Co-Founder and CEO, Montai Health & CEO-Partner, Chairman, Flagship Pioneering

Stephen Hahn, M.D.

CEO, Harbinger Health & CEO-Partner, Flagship Pioneering

Michael Nally, M.B.A.

CEO, Generate Biomedicines & CEO-Partner, Flagship Pioneering

Stephen H. Rusckowski

Co-Founder and CEO, Montai Health & CEO-Partner, Chairman, Flagship Pioneering

Mark Stevenson, M.B.A.

Former EVP & COO, Thermo Fisher Scientific

our advisors

Michele Andrasik, Ph.D.

Fred Hutchinson Cancer Research Center
Director, Social & Behavioral Sciences, Community Engagement
Operation Warp Speed

Sumithra Mandrekar, Ph.D.

Mayo Clinic
Lead faculty statistician for lung cancer research

John Mendlein, Ph.D.

Flagship Pioneering
Executive Partner

Scott Kopetz, M.D., Ph.D., FACP

MD Anderson Cancer Center
Professor, Department of Gastrointestinal Medical Oncology

Funda Meric-Bernstam, M.D.

MD Anderson Cancer Center
Chair Department of Investigational Cancer Therapeutics

Richard P. Shannon, M.D.

Duke University Health System
Chief Quality Officer
Board member, Kaiser Foundation

Robert A. Weinberg, Ph.D.

Massachusetts Institute of Technology Daniel K. Ludwig Professor for Cancer Research